US 11,702,480 B2
Engineered antibodies and uses thereof
Bin Liu, San Francisco, CA (US); Namkyung Lee, San Francisco, CA (US); Yang Su, San Francisco, CA (US); and Scott Bidlingmaier, San Francisco, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 16/349,958
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed Nov. 17, 2017, PCT No. PCT/US2017/062418
§ 371(c)(1), (2) Date May 14, 2019,
PCT Pub. No. WO2018/094282, PCT Pub. Date May 24, 2018.
Claims priority of provisional application 62/424,337, filed on Nov. 18, 2016.
Prior Publication US 2019/0330365 A1, Oct. 31, 2019
Int. Cl. C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 31/713 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/30 (2013.01) [A61K 31/713 (2013.01); C07K 16/2821 (2013.01); C07K 16/2866 (2013.01); C07K 16/468 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 17 Claims
 
1. An engineered protein comprising an antigen binding region that binds to a guide antigen and an antigen binding region that binds to an effector antigen; wherein the guide antigen and the effector antigen are expressed on the surface of a cell; wherein the antigen density of the guide antigen is at least four-fold higher than the antigen density of the effector antigen; wherein the guide antigen is ICAM-1, EphA2, or ALCAM, and the effector antigen is LRP6; and wherein
(a) the antigen binding region that binds the guide antigen ICAM-1 comprises all six complementarity determining regions (CDRs) of SEQ ID NO: 118,
(b) the antigen binding region that binds the guide antigen EphA2 comprises all six CDRs of SEQ ID NO: 121,
(c) the antigen binding region that binds the guide antigen ALCAM comprises all six CDRs of SEQ ID NO: 106, SEQ ID NO: 109, SEQ ID NO: 112, or SEQ ID NO: 115: and
(d) the antigen binding region that binds the effector antigen LRP6 comprises all six CDRs of SEQ ID NO: 4 or SEQ ID NO: 43.